Eone Diagnomics Genome Center KRX:245620KOSDAQ
EDGC · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Eone Diagnomics Genome Center reported revenue of ₩1.2bn, down 43.6% year on year, and an operating loss of ₩716m. Eone Diagnomics Genome Center (EDGC) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
Eone Diagnomics Genome Center quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.2bn | -43.6% | −₩716m margin −58.5% | −₩730m |
| Q1 2026 | ₩1.6bn | -67.4% | −₩1.3bn margin −81.4% | ₩24.7bn |
| Q4 2025 derived | ₩1.7bn | -70.3% | −₩359m margin −21.2% | ₩20.2bn |
| Q3 2025 | ₩1.8bn | -77.1% | −₩415m margin −23.2% | −₩436m |
| Q2 2025 | ₩2.2bn | -71.8% | −₩564m margin −26.0% | ₩5.5bn |
| Q1 2025 | ₩4.9bn | -49.5% | −₩1.5bn margin −31.0% | −₩525m |
| Q4 2024 derived | ₩5.7bn | -61.9% | −₩4.2bn margin −73.3% | −₩82.8bn |
| Q3 2024 | ₩7.8bn | -63.8% | −₩1.9bn margin −24.7% | −₩3.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Eone Diagnomics Genome Center top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Eone Diagnomics Genome Center news Korean headlines
No articles yet.